NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

Published

Journal Article

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

Full Text

Duke Authors

Cited Authors

  • Zelenetz, AD; Gordon, LI; Abramson, JS; Advani, RH; Bartlett, NL; Caimi, PF; Chang, JE; Chavez, JC; Christian, B; Fayad, LE; Glenn, MJ; Habermann, TM; Lee Harris, N; Hernandez-Ilizaliturri, F; Kaminski, MS; Kelsey, CR; Khan, N; Krivacic, S; LaCasce, AS; Mehta, A; Nademanee, A; Rabinovitch, R; Reddy, N; Reid, E; Roberts, KB; Smith, SD; Snyder, ED; Swinnen, LJ; Vose, JM; Dwyer, MA; Sundar, H

Published Date

  • June 1, 2019

Published In

Volume / Issue

  • 17 / 6

Start / End Page

  • 650 - 661

PubMed ID

  • 31200358

Pubmed Central ID

  • 31200358

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2019.0029

Language

  • eng

Conference Location

  • United States